## 



|CONTENTS|Page|
|---|---|
|LegalandAdministration||
|Chairman'sSummary|2|
|Trustees'Report|3-11|
|IndependentAuditors'Report|12-13|
|StatementofFinancialActivities|14|
|BalanceSheet|15|
|StatementofCashFlows|16|
|NotestotheFinancialStatements|17-24|





|<br> <br>**U**<br>ChangingLivesThrough<br>-<br>**LEGAL AND ADMINISTRATION **|**py **<br> Research|
|---|---|
|**TRUSTEES **|HenryRichard GeersCotterell(Chairman)|
||ReshmaAshrafMason|
||GuyEdmundSangster|
||JemmaFreeman|
||AlexanderJohns|
||SaffronGuy|
|**COMPANY SECRETARY **|ReshmaAshrafMason|
|**REGISTERED OFFICE **|BrydenJohnsonLimited|
||I-4 Kings Parade|
||LowerCoombeStreet|
||Croydon|
||CR0IAA|
|**DIRECTOR **|MarieDimond|
||Unit15|
||AbbevilleMews|
||88ClaphamParkRoad|
||London|
||SW47BX|
|**SECRETARY TO TRUSTEES **|Abigail Parry-Williams|
|**Fl ANCIAL ADVISOR **|DavidMcCormick|
|**AUDITORS **|BrydenJohnsonLimited|
||I-4KingsParade|
||LowerCoombeStreet|
||Croydon|
||CRO!AA|
|**SOLICITORS **|Ashurst|
||Broadwalk House|
||5AppoldStreet|
||LondonEC2A2HA|
|**PRINCIPAL BA~KERS **|BarclaysBankpie|
||KensingtonandChelsea|
||POBox4599|
||LondonSW3!XE|
|**INVESTMENT MANAGERS **|Cazenave CapitalManagement|
||12Moorgate|
||London|
||EC2R6DA|
|**GOVERJ'IING DOCUMENT **|TheMemorandumandArticlesofAssociationincorporated26ovember|
||1999as amended byspecialresolution dated30March 2000|





## 



## 

## 

## 

## 

## 

## 




## 

## 




## 

## 



## 

## 

## 







## 

||I|2021|**2020 **|
|---|---|---|---|
|**Total Income **||**£685,032 **|**£620,431 **|
|**Net (Deficit)/Gains including Investment Gains **||**£(109,147) **|**£(320,572) **|
|**Net Assets **||**£1,574,102 **|**£1,683,249 **|
|**Unrestricted Funds **||**£1,351,918 **|**£1,462,348 **|



## 















## 




## 

## 

## 

## 

## 

## 




## 

## 

## 

## 




|||**Unrestricted **|**Restricted **|**Total **||
|---|---|---|---|---|---|
|||**Funds **|**Funds **|**Funds **||
|||**2021 **|**2021 **|**2021 **|**2020 **|
||**Notes **|£|£|£|£|
|**lNCOME FROM: **||||||
|**Donations andlegacies **||221,976|460,938|682,914|590,781|
|**Charitable activities**||||||
|Symposium|||||19,058|
|Investmentincome||2,118||2,118|10,592|
|**Total income **||224,094|460,938|685,032|620,431|
|**EXPENDITUREON: **||||||
|Raisingfunds||65,478||65,478|73,022|
|Charitable activities||269,046|459,655|728,701|867,981|
|**Total expenditure **|2|334,524|459,655|794,179|941,003|
|**Net income/ (expenditure) before investment **||||||
|**(losses) **||(110,430)|1,283|(109,147)|(320,572)|
|etgain/(losses)oninvestments|7|||||
|**Net movement in funds **||(110,430)|1,283|(109,147)|(320,572)|
|**Balance brought forward 1 April 2020 **||1,462,348|220,90I|1,683,249|2,003,821|
|**Balance carried forward 31 March 2021 **|10,11|1,351,918|222,184|1,574,I02|1,683,249|







|||**2021 **||**2020 **||
|---|---|---|---|---|---|
||**Note **|£|£|£|£|
|**FIXED ASSETS **||||||
|Tangible assets|6||43,315||95,351|
|Investments|7||_1,193,498 _||1,342,633|
||||1,236,813||1,437,984|
|**CURRENT ASSETS **||||||
|Debtors|8|445,213||66,294||
|Cashatbankandinhand||74,635||359,082||
|||_519,848 _||425,376||
|**CREDITORS: Amounts falling **||||||
|**due withinone year **|9|(182,559)||(180,111)||
||||337,289||245,265|
|**NETASSETS **|||1,574,102||£1,683,249|
|Funds:||||||
|Unrestricted|10||1,351,918||1,462,348|
|Restricted|11||222,184||220,901|
||12||1,574,102||1,683,249|






## 

||**2021 **|**2020 **|
|---|---|---|
||£|£|
|**Cash from operating activities **|||
|Net cash(usedin)/by operatingactivities|(435,310)|(269,654)|
|**Cashflows from investing activities **|||
|Purchaseoffixedassets|(390)||
|Saleofinvestments|||
|Purchaseofinvestments|||
|Investmentincomereceived|2,118|10,592|
||1,728|10,592|
|(Decrease)/increaseincashandcashequivalentsintheyear|(433,582)|(259,062)|
|Cashandcashequivalentsatthebeginning oftheyear|||
||1,701,715|1,960,777|
|Cashandcashequivalentscarriedforward|1,268,133|1,701,715|
||======||
|**Reconciliation of net (expenditure)/income tonet cash flow **|||
|**from operating activities **|||
|Netmovementinfunds|(109,147)|(320,572)|
|Depreciationcharge|52,426|52,633|
|Investmentincome|(2,1I8)|(10,592)|
|(Decrease)/increaseincreditors|2,448|(398,087)|
|Decrease/(increase)in debtors|(378,919)|406,964|
||(435,310)|(269,654)|
|**Analysis of cash and cash equivalents **|||
|Cashatbank|74,635|359,082|
|Investments heldascash|1,193,498|1,342,633|
|Totalcashandcashequivalents|1,268,133|1,701,715|





## 

## 




## 

## 

## 

## 



|**2.**|**EXPENDITURE **|**2021 **|**2020 **|
|---|---|---|---|
|||£|£|
|**(a) **|**Raising funds **|||
||Fundraisingsalariesincludingnationalinsurance|79,991|61,842|
||Travel,subsistenceandrelatedexpenses|172|217|
||Events,committeemeetingsetc.|1,191|1,535|
||Marketingandpublicrelations|4,1224|4,201|
||Personnelcostsallocatedto Charitable&Admin|(20,000)||
||Investmentcharges||5,227|
|||65,478|73,022|
|**(b) **|**Charitable activities: **|||
||ContributiontoresearchfacilityatStGeorge'sUniversityofLondon|||
||-Staffincludingrecruitment|509,547|625,869|
||-Consumables|76,652|51,455|
||Symposium||58,377|
||Personnelcostsallocatedtocharitableexpenditure|10,000||
||Conference,travelandsubsistence|150|4,861|
||Legalandprofessionalfees-patent||3,690|
||Equipmentmaintenance|11,948|1,990|
||Equipmentdepreciation|51,032|51,032|
|||659,329|797,274|
||**Support **|||
||Rent,rates,andutilities|21,752|21,082|
||Telephone,printing,postage andstationery|11,785|15,451|
||Insurance|2,437|2,127|
||Bankandinvestment charges|3,353|265|
||Professionalfees|13|12,518|
||Depreciation|1,394|1,601|
||Personnelcostsallocatedto administration|10,000||
||Governance-Otherprofessionalcosts|4,000|4,660|
||Governance-Accountancy andaudit|14,638|13,003|
|||69,372|70,707|
||Total|794,179|941,003|
|**3.**|**STAFF COSTS **|**2021 **|**2020 **|
|||£|£|
||Wagesandsalaries|73,711|73,512|
||SocialSecurityCosts|3,748|4,763|
||Pensioncontributions|3,211|2,205|
|||79,670|80,480|





## 

## 

|`4. `|**'ET MOVEMENT IN FU~DS **|**2021 **|**2020 **|
|---|---|---|---|
|||£|£|
||Thisisstatedaftercharging:|||
||Depreciation|52,426|52,633|
||Auditors'remuneration|7,980|7,750|



|**6. **|**TANGIBLE FIXED ASSETS **|**Office furniture **|**Clinical **||
|---|---|---|---|---|
|||**and equipment **|**equipment **|**Total **|
|||£|£|£|
||**Cost **||||
||AtIApril2020|17,176|276,477|293,653|
||Additionsinyear|390||390|
||Disposalsin year|(11,129)|(I,150)|(12.279)|
||Asat31March2021|6437|275,327|28I,764|
||**Depreciation **||||
||AtIApril2020|15,380|182,922|198,302|
||Chargefortheyear|1,394|51,032|52,426|
||Eliminated ondisposal|(11,129)|(I,150)|(12,279)|
||At31March2021|5,645|232,804|238,449|
||**~ct Book Value **||||
||At31March2021|792|42,523|43,315|
||At31March2020|1,796|93,555|95,351|
|7.|**INVESTMENTS **||**2021 **|**2020 **|
||||£|£|
||Marketvalue atIApril2020||1,342,633|1,901,958|
||Additions||||
||Disposals||||
||Cashwithdrawals||(149,135)|(559,325)|
||Realisedlossonsale||||
||Unrealised(loss)/profit oninvestments||||
||Market valueat31March 2021||1,193,498|1,342,633|





|**8.**|**DEBTORS **|**2021 **|**2020**|
|---|---|---|---|
|||£|£|
||Prepaymentsandaccruedincome|37,178|55,467|
||Otherdebtors|408,035|10,827|
|||445,213|66,294|
|**9. **|**CREDITORS: AMOU~TS FALLl1\'G **|**2021 **|**2020**|
||**DUE WITHIN ONE YEAR **|£|£|
||Accrualsanddeferredincome|177,107|175,650|
||Othercreditors|5,452|4,461|
|||182,559|180,111|
|**10. **|**UNRESTRICTED FU 1DS **|**2021 **|**2020 **|
|||£|£|
||**General **|||
||AtIApril2020|1,462,348|1,729,036|
||(Deficit)forthefinancialyear|(110,430)|(266,688)|
||At31March 2021|1,351,918|1,462,348|





|**11.**|**RESTRICTED FUNDS **|**Balance at **|||**Balance at **|
|---|---|---|---|---|---|
|||**1April**|||**31 March **|
|||**2020**|**Income**|**Expenditure **|**2021 **|
|||£|£|£|£|
||Prostate CancerResearch|176,432|||176,432|
||Ovarian|42,947|1,562||44,509|
||Pancreatic|1,522||(1,522)||
||SeniorLecturerAssociate||20,413|(19,170)|1,243|
||Generalresearch||433,963|(426,355)||
||EquipmentCapital||5,000|(5,000)||
|||220,901|460,938|(459,655)|222,184|
||**RESTRICTED FUNDS **|**Balance at **|||**Balance at **|
|||**1April**|||**31 March **|
|||**2019 **|**Income**|**Expenditure **|**2020 **|
|||£|£|£|£|
||ProstateCancerResearch|176,432|||176,432|
||Ovarian||42,947||42,947|
||Pancreatic||1,522||1,522|
||SeniorLecturerAssociate|79,252||(79,252)||
||Generalresearch|13,279|413,076|(426,355)||
||Symposium|5,822|27,562|(33,384)||
|||274,785|485,107|(538,991)|220,901|






## 

|**12. **|**ANALYSTS OF NETASSETS **|**General **|**Restricted **|**Total **|
|---|---|---|---|---|
||**BETWEEN FUNDS **|**Funds **|**Funds **|**2021 **|
|||£|£|£|
||**Fund balances at31 March 2021 are represented by: **||||
||Tangibleassets|43,315||43,315|
||Investments|1,193,498||1,193,498|
||etcurrentassets|115,106|222,184|337,289|
|||1,351,918|222,184|1,574,102|
|||£|£|£|
||**Fund balances at 31 March 2020 are represented by: **||||
||Tangibleassets|95,351||95,351|
||Investments|1,342,633||1,342,633|
||et currentliabilities|24,364|220,901|245,265|
|||1,462,348|220,901|1,683,249|



## 

## 

## 

## 



|||**Unrestricted **|**Restricted **|**Total **|
|---|---|---|---|---|
|||**Funds **|**Funds **|**Funds **|
|||**2020 **|**2020 **|**2020 **|
||**Notes **|£|£|£|
|**l~COME FROM: **|||||
|**Donations and legacies **||I05,674|485,107|590,781|
|**Charitable activities **|||||
|Symposium||19,058||19,058|
|**Investment income **||10,592||10,592|
|**Total income **||135,324|485,I07|620,431|
|**EXPENDITURE ON: **|||||
|Raisingfunds||73,022||73,022|
|Charitableactivities||328,990|538,991|867,981|
|**Total expenditure **|2|402,012|538,991|941,003|
|**Net income/(expenditure) before investment **|||||
|**(losses) **||(266,688)|(53,884)|(320,572)|
|Net(losses)oninvestments|7||||
|**Net movement in funds **||(266,688)|(53,884)|(320,572)|
|**Balance brought forward **I**April20 **I9||1,729,036|274,785|2,003,821|
|**Balance carried forward 31 March 2020 **|10,11|1,462,348|220,901|1,683,249|